(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Hermine I. Brunner, MD, MSc, MBA Director, Division of Rheumatology
is a pediatric rheumatologist with a special interest in clinical and translational research, focusing on pediatric lupus. Her research is focused on biomarker discovery for children with lupus and the testing of new medications for various pediatric rheumatic diseases. Dr. Brunner is also involved in trial design and provides statistical support at Cincinnati Children's and is pioneering the development of outcome measures and improving the quality of care for children with lupus and other pediatric rheumatic diseases.
Visit the Brunner Lab.
Director, Division of Rheumatology
Professor, UC Department of Pediatrics
Health-related quality of life; outcome research; lupus
MD: Ludwig Maximilan University, Munich, Germany, 1991.
Residency: University of Chicago, 1997.
Fellowship: University of Toronto & Cincinnati, 1999.
MSc: Clinical Epidemiology: University of Toronto, 1999.
Certification: Pediatrics 1997; Rheumatology, 2002.
Brunner HI, Silva CA, Reiff A, Higgins GC, Imundo L, Williams CB, Wallace CA, Aikawa NE, Nelson S, Klein-Gitelman MS, Rose SR. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2015 May;67(5):1377-85.
De Benedetti F, Brunner H, Ruperto N, Schneider R, Xavier R, Allen R, Brown DE, Chaitow J, Pardeo M, Espada G, Gerloni V, Myones BL, Frane JW, Wang J, Lipman TH, Bharucha KN, Martini A, Lovell D; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015 Mar;67(3):840-8.
Brunner HI, Klein-Gitelman MS, Zelko F, Beebe DW, Foell D, Lee J, Zaal A, Jones J, Roebuck-Spencer T, Ying J. Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children. Lupus Sci Med. 2014 Nov 5;1(1):e000038.
Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F; Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015 Jun;74(6):1110-7.
Gitelman DR, Klein-Gitelman MS, Ying J, Sagcal-Gironella AC, Zelko F, Beebe DW, Difrancesco M, Parrish T, Hummel J, Beckwith T, Brunner HI. Brain morphometric changes associated with childhood-onset systemic lupus erythematosus and neurocognitive deficit. Arthritis Rheum. 2013 Aug;65(8):2190-200.
Hollander MC, Sage JM, Greenler AJ, Pendl J, Avcin T, Espada G, Beresford MW, Henrickson M, Lee TL, Punaro M, Huggins J, Stevens AM, Klein-Gitelman MS, Brunner HI. International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013 Sep;65(9):1416-23.
Mina R, Klein-Gitelman MS, Nelson S, Eberhard BA, Higgins G, Singer NG, Onel K, Tucker L, O'Neil KM, Punaro M, Levy DM, Haines K, Martini A, Ruperto N, Lovell D, Brunner HI. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis. 2014 Feb;73(2):401-6.
Brunner HI, Klein-Gitelman MS, Zelko F, Thomas EC, Hummel J, Nelson SM, Huggins J, Curran ML, Roebuck-Spencer T, Beebe DW, Ying J. Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus. Arthritis care & research. 2013;65(3):372-81.
Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken). 2012 Dec;64(12):1787-93.
Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, Hsu J, Klein-Gitelman M, Moorthy LN, Muscal E, Radhakrishna SM, Wagner-Weiner L, Adams M, Blier P, Buckley L, Chalom E, Chédeville G, Eichenfield A, Fish N, Henrickson M, Hersh AO, Hollister R, Jones O, Jung L, Levy D, Lopez-Benitez J, McCurdy D, Miettunen PM, Quintero-del Rio AI, Rothman D, Rullo O, Ruth N, Schanberg LE, Silverman E, Singer NG, Soep J, Syed R, Vogler LB, Yalcindag A, Yildirim-Toruner C, Wallace CA, Brunner HI; Carra SLE Subcommittee. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012 Mar;64(3):375-83.
Edward H. Giannini, MSc, DrPH
serves as project director for numerous clinical trials, and has vested a considerable part of his research career in the methodological aspects of conducting clinical trials in children with rheumatic diseases. In 2011 he received the ‘American College of Rheumatology Distinguished Clinical Investigator Award’ from among its 15,000 members.
Professor Emeritus, UC Department of Pediatrics
Dr. Giannini is a master of the American College of Rheumatology. In 2002 he was awarded the Arthritis Foundation’s Virginia P. Engalitcheff Award for Impact on Quality of Life of Persons with Arthritis. In 2011 he was named the Distinguished Clinical Investigator of the Year by the American College of Rheumatology.
MSc: Arizona State University, Tempe, AZ, 1975.
DrPH: University of Texas School of Public Health, Houston, TX, 1978.
Giannini EH, Ilowite NT, Lovell DJ et al. Effects of long-term etanercept on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis and Rheumatism. 2010;62:3259-3264.
Giannini EH, Mehta AB, Milz MJ, et al. A validated disease severity scoring system for Fabry Disease. Molecular Genetics and Metabolism. 2010;99:283-290.
Lovell DJ, Ruperto N, Goodman S.Giannini EH, Martini A. A randomized, placebo-controlled trial of adalimumab with or without methotrexate in children with polyarticular juvenile rheumatoid arthritis. New England Journal of Medicine. 2008;359:810-820.
Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck B, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular-course juvenile rheumatoid arthritis. New England Journal of Medicine. 2000;342:763-769.
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism. 1997;40:1202-1209.
Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS, for the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group: Methotrexate treatment of recalcitrant juvenile rheumatoid arthritis. Results of the U.S.A. - U.S.S.R. double-blind placebo-controlled trial. New England Journal of Medicine. 1992;326:1043-1049.
Giannini EH, Malagon C, Van Kerckhove C, Taylor J, Lovell DJ, Levinson JE, Passo MH, Ginsberg J, Burke M, Glass DN. Longitudinal analysis of HLA-associated risks for iridocyclitis in juvenile rheumatoid arthritis. Journal of Rheumatology. 1991;18:1394-1397.
Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. D - penicillamine and
hydroxychloroquine in the treatment of severe juvenile rheumatoid
arthritis: Results of the U.S.A. - U.S.S.R. double-blind, placebo
controlled trial. New England Journal of Medicine. 1986;314:1269-1276.
Giannini EH, Brewer EJ, Person DA. Auranofin in the treatment of juvenile rheumatoid arthritis. Journal of Pediatrics. 1983;102:138-141.
Giannini EH, Northey WT, Leathers CR. The allergic significance of certain fungi rarely reported as allergens. Annals of Allergy. 1975;35:372-376.
Alexei A. Grom, MD
The research of Alexei Grom, MD, has mainly involved two translational projects focused on two autoimmune diseases – systemic juvenile rheumatoid arthritis and juvenile dermatomyositis. In both projects, recent advances of cellular immunology are applied to these diseases to promote better understanding of their pathogenesis and treatment.
Systemic onset juvenile rheumatoid arthritis and an associated condition known as macrophage activation syndrome are severe and often devastating illnesses. The pathological mechanisms are not known but Dr. Alexei Grom has focused his research on NK and cytotoxic cell function in this disease. The rationale for this approach has been based on the strong clinical similarities between MAS and the better understood autosomal recessive disorder familial hemophagocytic lymphohistiocytosis, in which the uncontrolled proliferation of T cells and macrophages has been recently associated with decreased NK cell and cytotoxic cell functions secondary to mutations in the gene encoding perforin. Recent observations suggest as in FHLH, MAS patients also have profoundly depressed NK function. Moreover, a large subgroup of systemic JRA patients has very similar immunologic abnormalities. Combined with the evidence of the immunoregulatory role of NK cells in many immune responses, this suggests that NK dysfunction is relevant to the pathogenesis of MAS. New directions have thus been established for research in this poorly understood disease.
Juvenile dermatomyositis is a chronic inflammatory condition involving primarily muscles and skin. The most characteristic feature of JDM is vascular damage associated with the capillary necrosis that eventually leads to capillary loss and tissue ischemia. The project is based on the hypothesis that capillary loss in this condition may be caused by angiostatic chemokines that are prominent in the inflammatory response in the affected muscles.
MD: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1986.
Residency: Leningrad (St. Petersburg) Medical Institute, Russia, 1988; Children's Hospital Medical Center, Cincinnati, OH, 1998.
Fellowship: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1991; Children's Hospital Medical Center, Cincinnati, OH, 1995.
Certification: Pediatrics, 1999.
De Benedetti F, Brunner HI, Ruperto N, Kenwright, A, Ravelli A, Schneider, Woo P, Wouters C, Zemel, L, Burgos-Vargos R, Dolezalova P, Grom AA, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A. Tocilizumab in systemic juvenile idiopathic arthritis: a randomized trial. New Engl J Med. 367:2385-95. 2012.
Sikora KA, Fall N, Thornton S and Grom AA. A Markedly Low-Level of Interferon-Induced Gene Expression Distinguishes Active Systemic Juvenile Idiopathic Arthritis Synovium From other JIA subtypes: Implications for Pathogenesis of Macrophage Activation Syndrome. Arthritis Rheum. 64:3799-808. 2012.
Ruperto N, Brunner HI, Quartier P, Constantin T, Wulfraat N, Horneff G, Brik R, McCann L, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Grom AA, Magnusson, Ozen S, Abrams K, Kim D, Martini A, Lovell DJ. Canakinumab in systemic juvenile arthritis with active systemic features. New Engl J Med. 367:2396-406. 2012.
Mellins ED, Macubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nature Reviews Rheumatology. 7:416-26. 2011.
Sumegi J, Barnes MG, Lee S, Villanueva J, Zhang K, Nestheide SV, Risma K, Grom AA, AH Filipovich. Gene Expression Profiling of peripheral blood mononuclear cells from patients with untreated familial hemophagocytic lymphohistiocytosis. Blood. 117:151-60. 2011.
Barnes MG, Grom AA, Thompson SD, Griffin TA, Luyrink LK, Colbert, RA, David N, Glass DN. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 2010.
Hinze CH, Fall N, Thornton S, Griffin TA, Thompson SD, Colbert RA, Glass DN, Michael G, Barnes BG, Grom AA. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010.
Barnes MG, Grom AA, Thompson SD, Ilowite NT, Olson JC, Sherry DD, Gottlieb BS, Aronow BJ, Pavlidis P, Hinze C, Thornton S, Griffin TA, Colbert CA, DN Glass. Gene Expression Signatures in new onset untreated juvenile idiopathic arthritis. Arthritis Rheum. 60:2102-12. 2009.
Zhang K, Biroscak J, Glass DN, Thompson S, Finkel T, Murray P, Binstadt B, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13D polymorphisms. Arthritis Rheum. x58:2892-6. 2008.
Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb E, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA. Gene expression profiling in peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 56:3793-804. 2007.
Michael Henrickson, MD, MPH Director of Telemedicine, Division of Rheumatology
participates in numerous ongoing clinical research trials, as a feature of the Division of Rheumatology's translational research focus.
Director of Telemedicine, Division of Rheumatology
Associate Professor, UC Department of Pediatrics
Professor, University of Kentucky College of Medicine
Telehealth; health policy; global health; neuropsychiatric-SLE; periodic fever syndromes; systemic JIA; culturally appropriate care.
Dr. Henrickson has an abiding interest in serving as an advocate for his patients to ensure their complete health needs are addressed. He seeks to know the health care priorities of his patients and families and to fulfill them. To provide improved access to care for the limited resource of pediatric rheumatology, a priority for him is the development of telehealth capacity: tele-rheumatology.
BA: magna cum laude, Emory University, Atlanta, GA, 1980.
MD: Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, 1984.
MPH: College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2009.
Residency: Pediatrics, Department of Pediatrics, Tripler Army Medical Center, Honolulu, HI, 1984-87.
Fellowship: Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 1991-94.
Certification: American Board of Pediatrics: General Pediatrics, 1988 (recertified 2014); Pediatric Rheumatology, 1994 (recertified 2008); National Board of Public Health Examiners, 2009.
Weaver KN, El Hallek M, Hopkin RJ, Sund KL, Henrickson M, Del Gaudio D, Yuksel A, Acar GO, Bober MB, Kim J, Boyadjiev SA. Keutel syndrome: report of two novel MGP mutations and discussion of clinical overlap with arylsulfatase E deficiency and relapsing polychondritis. Am J Med Genet A. 2014; 164A(4):1062-8.
Patwardhan A, Henrickson M, Laskosz L, Hong SD, Spencer CH. Current pediatric rheumatology fellowship training in the United States: what fellows actually do. Pediatr Rheumatol Online J. 2014: 12(1):8.
Hollander MC, Sage JM, Greenler AJ, Pendl J, Avcin T, Espada G, Beresford MW, Henrickson M, Lee TL, Punaro M , Huggins J, Stevens AM, Marisa S. Klein-Gitelman MS, Brunner HI. International Consensus for Provisions of Quality-Driven Care in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2013; 65(9):1416-23.
Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, Hsu J, Klein-Gitelman M, Moorthy LN, Muscal E, Radhakrishna SM, Wagner-Weiner L, Adams M, Blier P, Buckley L, Chalom E, Chédeville G, Eichenfield A, Fish N, Henrickson M, Hersh AO, Hollister R, Jones O, Jung L, Levy D, Lopez-Benitez J, McCurdy D, Miettunen PM, Quintero-del Rio AI, Rothman D, Rullo O, Ruth N, Schanberg LE, Silverman E, Singer NG, Soep J, Syed R, Vogler LB, Yalcindag A, Yildirim-Toruner C, Wallace CA, Brunner HI; CARRA SLE Subcommittee. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012; 64(3):375-83.
Henrickson M. Policy Challenges for the Pediatric Rheumatology Workforce: Part I. Education and Economics. Pediatr Rheumatol Online J. 2011; 9:23.
Henrickson M. Policy Challenges for the Pediatric Rheumatology Workforce: Part II. Health Care System Delivery and Workforce Supply. Pediatr Rheumatol Online J. 2011; 9:24.
Henrickson M. Policy Challenges for the Pediatric Rheumatology Workforce: Part III. The International Situation. Pediatr Rheumatol Online J. 2011; 9:26.
Lovell DJ, Henrickson M, DeWitt EM, Segerman J, Taylor J, Giannini EH, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Ilowite NT, Kimura Y, Stein LD, Vehe RK. Pain as a quality of care measure in juvenile idiopathic arthritis: one step forward, but is it the best foot? Comment on the article by Lovell et al. Reply. Arthritis Care Res (Hoboken). 2011; 63(9):1353.
Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, Dewitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care. A proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011; 63(1):10-16.
Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Xu S, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010; 69(4):718-22.
Jennifer L. Huggins, MD Fellowship Program Director, Division of Rheumatology
Fellowship Program Director, Division of Rheumatology
Dr. Huggins is board certified in pediatrics, internal medicine, allergy/immunology, pediatric and adult rheumatology. She was a primary care provider for internal medicine/pediatrics for 12 years before entering fellowship training for allergy/immunology/rheumatology. As a result of her primary care experience she is aware of the importance and complexities of vaccine administration. In addition to her responsibilities as the Pediatric Rheumatology Fellowship program director, she cares for a significant number of patients with juvenile idiopathic arthritis (JIA) as well as systemic lupus erythematosus (SLE) in the division. Her current caseload includes over 70% of the SLE patients at Cincinnati Children’s. Dr. Huggins has already begun a pilot quality improvement project on improving the administration of appropriate pneumococcal vaccination in our SLE patients. This project builds logically on her previous primary care experience and current clinical work, and commitment to improving vaccination protection for immunocompromised patients.
MD: University of Kansas Medical School, Kansas City, KS.
Residency: Baylor College of Medicine, 1986.
Fellowship: Allergy/Immunology and Rheumatology, University of Rochester School of Medicine, 2005.
Fellowship: Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, 2007.
Daniel J. Lovell, MD, MPH Associate Director, Division of Rheumatology
focuses on the performance of interventional clinical trials in children with juvenile idiopathic arthritis (JIA) and other rheumatic diseases. He has served as the PI for >30 multicenter, interventional trials in JIA. Dr. Lovell is also involved in the development and validation of outcome measures and clinical response definitions for JIA, JDM and childhood onset systemic lupus erythematosus (SLE).
Associate Director, Division of Rheumatology
Diagnostic evaluation and ongoing care of children with all pediatric onset rheumatic diseases
MD: University of Kansas, Kansas City, KS, 1978.
MPH: University of Texas School of Public Health, Houston, TX, 1982.
Residency: Children's Mercy Hospital, Kansas City, KS.
Fellowship: Baylor College of Medicine, Houston, TX.
Certification: Pediatrics, 1984; Pediatric Rheumatology, 1992.
Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6.
Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov;62(11):3259-64.
Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009 Sep;60(9):2794-804.
Seid M, Opipari L, Huang B, Brunner HI, Lovell DJ. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Rheum. 2009 Mar 15;61(3):393-9.
Carrasco R, Lovell DJ, Giannini EH, Henderson CJ, Huang B, Kramer S, Ranz J, Heubi J, Glass D. Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial. Arthritis Rheum. 2008 Dec;58(12):3932-40.
Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008 Aug 21;359(8):810-20.
Ting TV, Lovell DJ. Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis? Nat Clin Pract Rheumatol. 2008 Jul;4(7):344-5.
Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008 May;58(5):1496-504.
Shishov M, Henrickson M, Burgos-Vargas R, Rubio-Pérez N, Baca V, Romero-Feregrino R, Solís-Vallejo E, Huang B, Grom AA, Lovell DJ. Systemic features and early prognostic factors in Hispanic and non-Hispanic children from the United States of America and Mexico with systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):907-14.
Lovell DJ. Update on treatment of arthritis in children: new treatments, new goals. Bull NYU Hosp Jt Dis. 2006;64(1-2):72-6. Review.
Esi Morgan DeWitt, MD, MSCE
focuses on the development and validation of patient reported outcomes measures using modern psychometric approaches, including item response theory, for improved health assessment in children. A second major research focus concerns improving clinical outcomes of patients with juvenile idiopathic arthritis through the science of quality improvement.
Childhood rheumatic diseases; juvenile idiopathic arthritis; juvenile dermatomyositis; sarcoidosis
Esi Morgan DeWitt, MD, MSCE, is a pediatric rheumatologist and researcher. Clinical care spans the childhood rheumatic diseases, with focus on juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis.
Her research training and experience includes epidemiology and health services research, in addition to specialization in quality improvement methods and application to improve health care delivery. Dr. Morgan DeWitt leads a research project to develop new measures to assess pain in children and youth, as well as to validate measures of health related quality of life in children with juvenile idiopathic arthritis or chronic pain as part of a national network of investigators.
Dr. Morgan DeWitt is a leader in a multi-center quality improvement network to improve the outcome of care in children with JIA, the Pediatric-Rheumatology Care and Outcomes Improvement Network. Additionally, she has served on expert panels in development of JIA treatment recommendations and measures of quality of care in treatment of JIA.
MD: Washington University School of Medicine, St. Louis, MO, 1999.
Residency: Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, 2002.
Fellowship: Rheumatology, Children’s Hospital of Philadelphia, Philadelphia, PA, 2005.
MSCE: University of Pennsylvania, Center for Clinical Epidemiology & Biostatistics, Philadelphia, PA, 2005.
Certification: Pediatrics, 2002; Pediatric Rheumatology, 2006.
Dewitt EM, Stucky BD, Thissen D, Irwin DE, Langer M, Varni JW, Lai JS, Yeatts KB, Dewalt DA. Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theory. J Clin Epidemiol. 2011 Jul;64(7):794-804.
Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011 Apr;63(4):465-82.
Dinan MA, Compton KL, Dhillon JK, Hammill BG, Dewitt EM, Weinfurt KP, Schulman KA. Use of patient-reported outcomes in randomized, double-blind, placebo-controlled clinical trials. Med Care. 2011 Apr;49(4):415-9.
Varni JW, Stucky BD, Thissen D, Dewitt EM, Irwin DE, Lai JS, Yeatts K, Dewalt DA. PROMIS Pediatric Pain Interference Scale: An item response theory analysis of the Pediatric Pain Item Bank. J Pain. 2010 Nov;11(11):1109-19.
Irwin DE, Stucky BD, Thissen D, Dewitt EM, Lai JS, Yeatts K, Varni JW, DeWalt DA. Sampling plan and patient characteristics of the PROMIS pediatrics large – scale survey. Qual Life Res. 2010 May;19(4):585-94.
DeWitt EM, Lin L, Glick HA, Anstrom KJ, Schulman KA, Reed SD. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther. 2009 Aug; 31(8):1871-80; discussion 1858.
Morgan DeWitt E, Glick HA, Albert DA, Joffe M, Wolfe F. Medicare coverage of tumor necrosis factor α inhibitors as an influence on physicians’ prescribing behavior. Arch of Intern Med. 2006;166:57-63.
DeWitt EM, Schanberg LE, Rabinovich CE. Treatment of Rheumatic Diseases. In RM Kleigman, BM Stanton, J St. Geme, N Schor, RE Behrman (Eds.), Nelson Textbook of Pediatrics. 19th ed. Elsevier Saunders: Philadelphia, PA, 2011.
Wu EY, DeWitt, EM. Sarcoidosis. In RM Kleigman, BM Stanton, J St. Geme, N Schor, RE Behrman (Eds.), Nelson Textbook of Pediatrics.19th ed. Elsevier Saunders: Philadelphia, PA, 2011.
Grant Schulert, MD, PhD
is focused on mechanisms of innate immunity and inflammation, specifically as they relate to rheumatic diseases in children. In particular he investigates the function and regulation of monocytes and macrophages during systemic inflammation. He also focuses on use of genomic approaches to define the risk for systemic inflammatory diseases
Instructor, UC Department of Pediatrics
Pediatric rheumatology; juvenile idiopathic arthritis; macrophage activation syndrome; autoinflammatory syndromes; periodic fevers
MD: University of Iowa College of Medicine, Iowa City, IA, 2009.
PhD: University of Iowa Department of Microbiology, Iowa City, IA, 2009.
Residency: Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Fellowship: Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 2012.
Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145-59.
Schulert GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, Zhang K, Davis K, Jentzen JM, Napolitano L, Siddiqui J, Smith LB, Harms PW, Grom AA, Cron RQ. Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza. J Infect Dis. 2015 Nov 23.
Schulert GS, Bove K, McMasters R, Campbell K, Leslie N, Grom AA. 11-Month-Old Infant With Periodic Fevers, Recurrent Liver Dysfunction, and Perforin Gene Polymorphism. Arthritis Care Res (Hoboken). 2015 Aug;67(8):1173-9.
Schulert GS, Grom AA. Macrophage activation syndrome and cytokine directed therapy. Best Prac Res Clin Rheumatol. 2014;28:277-292.
Schulert GS, Graham TB. Chronic inflammatory arthritis of the ankle/hindfoot/midfoot complex in children with extreme obesity. J Clin Rheumatol. 2014 Sep;20(6):317-21.
Schulert GS, McCaffrey RL, Buchan BW, Lindemann SR, Hollenback C, Jones BD, Allen LA. Francisella tularensis genes required for inhibition of the neutrophil respiratory burst and intramacrophage growth identified by random transposon mutagenesis of strain LVS. Infect Immun. 2009 Apr;77(4):1324-36.
Schulert GS, Allen LA. Differential infection of mononuclear phagocytes by Francisella tularensis: role of the macrophage mannose receptor. J Leukoc Biol. 2006 Sep;80(3):563-71.
Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, Schulert GS, McColley SA, Hauser AR. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during respiratory colonization in cystic fibrosis. J Clin Micro. 2004;42:5229-5237.
Schulert GS, Feltman H, Rabin SD, Martin CG, Battle SE, Rello J, Hauser AR. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis. 2003 Dec 1;188(11):1695-706. Epub 2003 Nov 21.
Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology. 2001 Oct;147(Pt 10):2659-69.
Contribution of microRNA to aberrant monocyte activation and polarization in systemic juvenile idiopathic arthritis. Principal Investigator. Rheumatology Research Foundation. Jul 2015-Jun 2017.
Genomics of Reactive Hemophagocytic Lymphohistiocytosis. Trainee. National Institutes of Health/National Heart, Lung, and Blood Institute. May 2014-Apr 2016.
Sherry L. Thornton, PhD
Field Service Associate Professor, UC Department of Pediatrics
Evaluating targets for the treatment of rheumatic disease; angiogenesis; animal models of arthritis
Visit the Grom-Thornton Lab.
BS: Ball State University, Muncie, IN.
PhD: University of Cincinnati, College of Medicine, Cincinnati, OH.
Postdoctoral Research Fellow: Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Hinze CH, Fall N, Thornton S, Mo JQ, Aronow BJ, Layh-Schmitt G, Griffin TA, Thompson SD, Colbert RA, Glass DN, Barnes MG, Grom AA. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010;12(3):R123.
Griffin TA, Barnes MG, Ilowite NT, Olson JC, Sherry DD, Gottlieb BS, Aronow BJ, Pavlidis P, Hinze CH, Thornton S, Thompson SD, Grom AA, Colbert RA, Glass DN. Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis Rheum. 2009 Jul;60(7):2113-23.
Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007 Nov;56(11):3793-804.
Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007 Nov;117(11):3224-35.
Fall N, Bove KE, Stringer K, Lovell DJ, Brunner HI, Weiss J, Higgins GC, Bowyer SL, Graham TB, Thornton S, Grom AA. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum. 2005 Oct;52(10):3175-80.
Carey B, DeLay M, Strasser JE, Chalk C, Dudley-McClain K, Milligan GN, Brunner HI, Thornton S, Hirsch R. A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. Clin Immunol. 2005 Jul;116(1):65-76.
Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, Jiang X. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol. 2005 Jun;79(11):6714-22.
Hermann LM, Pinkerton M, Jennings K, Yang L, Grom A, Sowders D, Kersten S, Witte DP, Hirsch R, Thornton S. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol. 2005 Apr;115(1):93-101.
Katakura S, Jennings K, Watanabe S, Adachi E, Thornton S, Gao GP, Wilson JM, Burstein H, Trapnell B, Hirsch R. Recombinant adeno-associated virus preferentially transduces human, compared to mouse, synovium: implications for arthritis therapy. Mod Rheumatol. 2004;14(1):18-24.
Tracy V. Ting, MD, MSc, RhMSUS
Assistant Professor, UC Department of Pediatrics
Fibromyalgia; joint hypermobility; juvenile idiopathic arthritis (JIA); systemic lupus erythematosus (SLE)
MD: West Virginia University, Morgantown, WV, 2002.
Residency: Cleveland Clinic, Cleveland, OH, 2005.
Certification: Pediatrics, 2005; Pediatric Rheumatology, 2011.
Sil S, Thoomas S, DiCesare C, Strotman D, Ting TV, Myer G, Kashikar-Zuck S. Preliminary evidence of altered biomechanics in adolescents with Juvenile Fibromyalgia. Arthritis Care Res. 2014 Aug 22.
Sil S, Arnold LM, Lynch-Jordan A, Ting TV, Peugh J, Cunningham N, Powers SW, Lovell DJ, Hashkes PJ, Passo M, Schikler KN, Kashikar-Zuck S. Identifying treatment responders and predictors of improvement after cognitive-behavioral therapy for juvenile fibromyalgia. Pain. 2014;155(7):1206-12.
Kashikar-Zuck S, Cunningham N, Sil S, Bromberg MH, Lynch-Jordan AM, Strotman D, Peugh J, Noll J, Ting TV, Powers SW, Lovell DJ, Arnold LM. Long-term outcomes of adolescents with juvenile-onset fibromyalgia in early adulthood. Pediatrics. 2014;133(3):e592-600.
Kashikar-Zuck S, Ting TV. Juvenile fibromyalgia: current status of research and future developments. Nat Rev Rheumatol. 2014;10(2):89-96.
Joffe NE, Lynch-Jordan A, Ting TV, Arnold LM, Hashkes PJ, Lovell DJ, Passo MH, Powers SW, Schikler KN, Kashikar-Zuck S. The utility of the PedsQL™ Rheumatology Module as an outcome measure in juvenile fibromyalgia. Arthritis Care Res. 2013 Nov;65(11):1820-7.
Verkamp EK, Flowers SR, Lynch-Jordan AM, Taylor J, Ting TV, Kashikar-Zuck S. A survey of conventional and complementary therapies used by youth with juvenile-onset fibromyalgia. Pain Manag Nurs. 2013;14(4):e244-50.
Kashikar-Zuck S, Sil S, Lynch-Jordan AM, Ting TV, Peugh J, Schikler KN, Hashkes PJ, Arnold LM, Passo M, Richards-Mauze MM, Powers SW, Lovell DJ. Changes in pain coping, catastrophizing, and coping efficacy after cognitive-behavioral therapy in children and adolescents with juvenile fibromyalgia. J Pain. 2013;14(5):492-501.
Kashikar-Zuck S, Zafar M, Barnett KA, Aylward BS, Strotman D, Slater SK, Allen JR, LeCates SL, Kabbouche MA, Ting TV, Hershey AD, Powers SW. Quality of life and emotional functioning in youth with chronic migraine and juvenile fibromyalgia. Clin J Pain. 2013;29(12):1066-72.
Kashikar-Zuck S, Flowers SR, Strotman D, Sil S, Ting TV, Schikler KN. Physical activity monitoring in adolescents with juvenile fibromyalgia: Findings from a clinical trial of cognitive behavioral therapy. Arthritis Care Res. 2013;65(3):903-9.
Sil S, Lynch-Jordan A, Ting TV, Peugh J, Noll J, Kashikar-Zuck S. The influence of family environment on long-term psychosocial functioning of adolescents with juvenile fibromyalgia. Arthritis Care Res. 2012;65(6):903-9.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center. All rights reserved.